ATE278694T1 - Verfahren zur herstellung von substituierte piperidinepoxiden - Google Patents

Verfahren zur herstellung von substituierte piperidinepoxiden

Info

Publication number
ATE278694T1
ATE278694T1 AT99115244T AT99115244T ATE278694T1 AT E278694 T1 ATE278694 T1 AT E278694T1 AT 99115244 T AT99115244 T AT 99115244T AT 99115244 T AT99115244 T AT 99115244T AT E278694 T1 ATE278694 T1 AT E278694T1
Authority
AT
Austria
Prior art keywords
poxides
aryl
substituted piperidine
producing substituted
cycloalkyl
Prior art date
Application number
AT99115244T
Other languages
English (en)
Inventor
Rolf Gueller
Bruno Lohri
Rudolf Schmid
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE278694T1 publication Critical patent/ATE278694T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT99115244T 1998-08-10 1999-08-02 Verfahren zur herstellung von substituierte piperidinepoxiden ATE278694T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98114975 1998-08-10

Publications (1)

Publication Number Publication Date
ATE278694T1 true ATE278694T1 (de) 2004-10-15

Family

ID=8232436

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99115244T ATE278694T1 (de) 1998-08-10 1999-08-02 Verfahren zur herstellung von substituierte piperidinepoxiden

Country Status (10)

Country Link
US (1) US6268499B1 (de)
EP (1) EP0979824B1 (de)
JP (1) JP3366290B2 (de)
KR (1) KR100331516B1 (de)
CN (1) CN1111534C (de)
AT (1) ATE278694T1 (de)
CA (1) CA2279817C (de)
DE (1) DE69920834T2 (de)
DK (1) DK0979824T3 (de)
ES (1) ES2229599T3 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2780056B1 (fr) * 1998-06-18 2000-08-04 Hoechst Marion Roussel Inc Nouveau procede de preparation de derives de la 4-phenyl-1-2 3,6-tetrahydropyridine et les produits imtermediaires mis en oeuvre
MX2017013383A (es) 2015-04-20 2017-12-07 Tolero Pharmaceuticals Inc Prediccion de respuesta a alvocidib mediante perfilado mitocondrial.
PT3298021T (pt) 2015-05-18 2019-08-05 Tolero Pharmaceuticals Inc Pró-fármacos de alvocidib possuindo biodisponibilidade aumentada
CA2993659A1 (en) 2015-08-03 2017-02-09 Tolero Pharmaceuticals, Inc. Combination therapies for treatment of cancer
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
EP3395806B1 (de) * 2017-04-24 2020-04-08 IGM Group B.V. Einfache oxidative funktionalisierung von alkylarylketonen
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3954876A (en) 1972-01-24 1976-05-04 Yeda Research And Development Co., Ltd. Production of halo-substituted derivatives of acetophenone
DE2600557A1 (de) * 1976-01-09 1977-07-14 Delmar Chem 4-aryl-3/4-amino/hydroxy-piperidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
BR9610385A (pt) 1995-09-07 1999-07-06 Hoffmann La Roche Novas 4-(oxalcoxifenil)-3-óxi-piperidinas para tratamento de insuficiência cardiáca e renal
US6274735B1 (en) 1998-08-10 2001-08-14 Hoffmann-La Roche Inc. Process and intermediates for preparation of substituted piperidines

Also Published As

Publication number Publication date
KR100331516B1 (ko) 2002-04-06
DK0979824T3 (da) 2005-02-07
EP0979824A1 (de) 2000-02-16
DE69920834T2 (de) 2005-12-08
US6268499B1 (en) 2001-07-31
CA2279817A1 (en) 2000-02-10
CA2279817C (en) 2005-04-12
CN1245805A (zh) 2000-03-01
ES2229599T3 (es) 2005-04-16
KR20000017193A (ko) 2000-03-25
CN1111534C (zh) 2003-06-18
EP0979824B1 (de) 2004-10-06
JP2000063383A (ja) 2000-02-29
JP3366290B2 (ja) 2003-01-14
DE69920834D1 (de) 2004-11-11

Similar Documents

Publication Publication Date Title
ATE174589T1 (de) Verfahren zur herstellung von piperidinderivaten
HUT63305A (en) Fungicidal compositions comprising triazolopyrimidine derivatives and process for producing the triazolopyrimidine derivatives
DE69534029D1 (de) Herstellung von Camptothecinderivaten durch intramolekulare Cyclisierung
ATE393144T1 (de) Verfahren zur herstellung substituierter 3- hydroxypiperidine
ATE278694T1 (de) Verfahren zur herstellung von substituierte piperidinepoxiden
ATE442363T1 (de) Verfahren zur herstellung von pyridinverbindungen
ATE531702T1 (de) Verfahren zur herstellung von epoxytriazolderivat und zwischenprodukten dafür
DE69231815D1 (de) Verfahren zur Herstellung von Cephalosporinen und Zwischenprodukte in diesem Verfahren
ATE343385T1 (de) Verfahren zur herstellung von donepezil
ATE311382T1 (de) Verfahren zur herstellung von 2-carbamoyl- pyridinen
ATE189453T1 (de) Verfahren zur herstellung von 2-cyanobiphenyl- verbindungen
ATE155132T1 (de) Verfahren zur herstellung von amino- thiadiazolylacetylhaliden
ATE223377T1 (de) Verfahren zur herstellung von difluoracetophenon- derivaten
ATE142195T1 (de) Verfahren zur herstellung von fluorbenzolderivaten und verwandter verbindungen
ATE228993T1 (de) Verfahren zur herstellung von 1,1,1-trifluoro-2- aminoalkane
ATE212613T1 (de) Verfahren zur herstellung von 1,7-diaryl- oder 1, 7-diheteroarylheptan-4-olen und synthesezwischenprodukte
DK0455304T3 (da) Fremgangsmåde til fremstilling af cykliske ketoner
ATE101595T1 (de) Verfahren zur herstellung von carbamaten und dabei auftretende zwischenprodukte.
ATE370146T1 (de) Verfahren zur herstellung von cephalosporin- derivaten
DE69716370T2 (de) Verfahren zur herstellung von beta-lactam verbindungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0979824

Country of ref document: EP

REN Ceased due to non-payment of the annual fee